hMPV_Y low dose vaccine

Preclinical

hMPV_Y low dose vaccine is one of 4 therapeutic programs targeting Respiratory Syncytial Virus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Respiratory Syncytial VirusRecruiting

Respiratory Syncytial VirusPreclinical

Recruiting

Competition

Competitive Landscape

21 competitors in Respiratory Syncytial Virus

#DrugCompanyPhaseTrials

Placebp

Pfizer

Phase 3

1 2

Mrna-1345

Moderna

Phase 1

3 3

Nimenrix

GSK

Phase 1

2 4

hMPV_Y low dose vaccine

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalRecruiting

Respiratory Syncytial Virus

NCT07628049

Clinical

Trials by Indication[1]

Respiratory Syncytial Virus1 trial

A Phase 1/2, Randomized, Controlled, Observer-blind, Multicentre Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of GSK Biologicals' Investigational Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) Combination and Investigational hMPV Vaccines When Administered Intramuscularly According to a Single Dose Schedule in Younger Adults ≥18 to ≤49 Years and Older Adults Aged ≥60 to ≤80 Years

Recruiting· GSK logo

GSK·Preclinical·NCT07628049·1,808 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for hMPV_Y low dose vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for hMPV_Y low dose vaccine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: GSK

hMPV_Y low dose vaccine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Respiratory Syncytial Virus1 trial

References

Drug Info

Quick Facts

Related News